Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 181
Filter
1.
Nutrients ; 16(14)2024 Jul 22.
Article in English | MEDLINE | ID: mdl-39064816

ABSTRACT

Given the limited evidence, there is no conclusive proof of the neurocognitive benefits of bovine milk fat globule membrane supplementation in infant formula. This study evaluates the neurocognitive benefits of bovine milk fat globule membrane supplementation in formula, comparing it to standard formula and assessing its noninferiority to breast milk. Data were sourced from studies published between January 2000 and March 2024 from PubMed, Cochrane Library, Web of Science, and Embase. Eight randomized controlled trials involving 1352 healthy term neonates, infants, and children up to 2 years old were included. Bovine milk fat globule membrane supplementation was significantly associated with improved cognitive development (mean difference: 3.29, 95% CI: 1.65 to 4.93, p < 0.001) and demonstrated minimal heterogeneity (I2 = 0%, p = 0.564). It showed significant improvement in executive function but not in language, motor, or social-emotional development. In non-inferiority analysis, there was no significant difference compared to breast milk regarding cognitive development. These findings support bovine milk fat globule membrane as a valuable addition to infant formula for cognitive benefits.


Subject(s)
Child Development , Cognition , Dietary Supplements , Glycolipids , Glycoproteins , Infant Formula , Lipid Droplets , Glycolipids/administration & dosage , Animals , Infant , Humans , Cognition/drug effects , Cattle , Infant, Newborn , Randomized Controlled Trials as Topic , Female , Milk, Human/chemistry , Child, Preschool , Infant Nutritional Physiological Phenomena , Male , Milk/chemistry
2.
BMJ Open ; 14(6): e083399, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38951000

ABSTRACT

INTRODUCTION: Milk fat globule membrane (MFGM) is a complex lipid-protein structure in mammalian milk and human milk that is largely absent from breastmilk substitutes. The objective of this trial is to investigate whether providing infant formula enriched with MFGM versus standard infant formula improves cognitive development at 12 months of age in exclusively formula-fed full-term infants. METHODS AND ANALYSIS: This is a randomised, controlled, clinician-blinded, researcher-blinded and participant-blinded trial of two parallel formula-fed groups and a breastfed reference group that were recruited in the suburban Adelaide (Australia) community by a single study centre (a medical research institute). Healthy, exclusively formula-fed, singleton, term-born infants under 8 weeks of age were randomised to either an MFGM-supplemented formula (intervention) or standard infant formula (control) from enrolment until 12 months of age. The reference group was not provided with formula. The primary outcome is the Cognitive Scale of the Bayley Scales of Infant Development, Fourth Edition (Bayley-IV) at 12 months. Secondary outcomes are the Bayley-IV Cognitive Scale at 24 months, other Bayley-IV domains (language, motor, emotional and behavioural development) at 12 and 24 months of age, infant attention at 4 and 9 months of age, parent-rated language at 12 and 24 months of age, parent-rated development at 6 and 18 months of age as well as growth, tolerance and safety of the study formula. To ensure at least 80% power to detect a 5-point difference in the mean Bayley-IV cognitive score, >200 infants were recruited in each group. ETHICS AND DISSEMINATION: The Women's and Children Health Network Human Research Ethics Committee reviewed and approved the study (HREC/19/WCHN/140). Caregivers gave written informed consent prior to enrolling in the trial. Findings of this study will be disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: ACTRN12620000552987; Australian and New Zealand Clinical Trial Registry: anzctr.org.au.


Subject(s)
Child Development , Cognition , Glycolipids , Glycoproteins , Infant Formula , Lipid Droplets , Humans , Glycolipids/administration & dosage , Infant Formula/chemistry , Glycoproteins/administration & dosage , Cognition/drug effects , Infant , Female , Infant, Newborn , Male , Randomized Controlled Trials as Topic , Dietary Supplements , Breast Feeding , Milk, Human/chemistry
3.
AAPS PharmSciTech ; 25(6): 177, 2024 Jul 31.
Article in English | MEDLINE | ID: mdl-39085675

ABSTRACT

Acne affects most of the world's population, causing an impact on the self-esteem of adolescents and young adults. One of the causes is the presence of the bacteria Cutibacterium acnes which are part of the natural microbiota of the skin. Topical treatments consist of anti-inflammatory and antibiotics, which could select resistant strains. Alternatives to the antibiotic are biocomposites that have antimicrobial activity like biosurfactants which are produced by bacteria. An innovative way of applying these compounds is bioadhesive polymeric films that adhere to the skin and release the active principle topically. Rhamnolipids have great potential to be used in the treatment of acne because they present antimicrobial activity against C. acnes in low and safe concentrations (MIC of 15.62 µg/mL, CBM of 31.25 µg/mL and CC50 of 181.93 µg/mL). Four films with different rhamnolipids concentrations (0.0; 0.1; 0.2; and 0.3%, w/w) were obtained as to visual appearance, mass variation, thickness, density, solubility, pH, water vapor transmission, mechanical properties (folding endurance, bioadhesion strength, tensile strength, elongation at break and Young's modulus), scanning electron microscopy and infrared. The results show that these formulations had a homogeneous appearance; elastic mechanical properties; pH similar to human skin and bioadhesive. The polymeric films containing rhamnolipids were effective against C. acnes, in the in vitro test, at the three concentrations tested, the film with the highest concentration (0.3%, w/w) being the most promising for presenting the highest antimicrobial activity. Thus, the polymeric film containing rhamnolipids has the potential to be used in the treatment of acne.


Subject(s)
Glycolipids , Microbial Sensitivity Tests , Polymers , Glycolipids/chemistry , Glycolipids/administration & dosage , Glycolipids/pharmacology , Polymers/chemistry , Microbial Sensitivity Tests/methods , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/chemistry , Administration, Topical , Propionibacterium acnes/drug effects , Acne Vulgaris/drug therapy , Humans , Skin/drug effects , Solubility , Anti-Infective Agents/pharmacology , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/chemistry , Tensile Strength , Chemistry, Pharmaceutical/methods
4.
Int J Pharm ; 661: 124458, 2024 Aug 15.
Article in English | MEDLINE | ID: mdl-38996823

ABSTRACT

Leukemia, particularly acute myeloid leukemia (AML) is considered a serious health condition with high prevalence among adults. Accordingly, finding new therapeutic modalities for AML is urgently needed. This study aimed to develop a biocompatible nanoformulation for effective oral delivery of the phytomedicine; baicalin (BAC) for AML treatment. Lipid nanocapsules (LNCs) based on bioactive natural components; rhamnolipids (RL) as a biosurfactant and the essential oil linalool (LIN), were prepared using a simple phase-inversion method. The elaborated BAC-LNCs displayed 61.1 nm diameter and 0.2 PDI. Entrapment efficiency exceeded 98 % with slow drug release and high storage-stability over 3 months. Moreover, BAC-LNCs enhanced BAC oral bioavailability by 2.3-fold compared to BAC suspension in rats with higher half-life and mean residence-time. In vitro anticancer studies confirmed the prominent cytotoxicity of BAC-LNCs on the human leukemia monocytes (THP-1). BAC-LNCs exerted higher cellular association, apoptotic capability and antiproliferative activity with DNA synthesis-phase arrest. Finally, a mechanistic study performed through evaluation of various tumor biomarkers revealed that BAC-LNCs downregulated the angiogenic marker, vascular endothelial growth-factor (VEGF) and the anti-apoptotic marker (BCl-2) and upregulated the apoptotic markers (Caspase-3 and BAX). The improved efficacy of BAC bioactive-LNCs substantially recommends their pharmacotherapeutic potential as a promising nanoplatform for AML treatment.


Subject(s)
Drug Liberation , Flavonoids , Leukemia, Myeloid, Acute , Nanocapsules , Animals , Flavonoids/pharmacology , Flavonoids/administration & dosage , Flavonoids/chemistry , Humans , Leukemia, Myeloid, Acute/drug therapy , Nanocapsules/chemistry , Male , Apoptosis/drug effects , Rats , Glycolipids/chemistry , Glycolipids/administration & dosage , Glycolipids/pharmacology , Monoterpenes/pharmacology , Monoterpenes/chemistry , Monoterpenes/administration & dosage , THP-1 Cells , Biological Availability , Administration, Oral , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/pharmacokinetics , Antineoplastic Agents, Phytogenic/chemistry , Rats, Sprague-Dawley , Cell Proliferation/drug effects , Cell Line, Tumor , Acyclic Monoterpenes
5.
J Nutr Sci Vitaminol (Tokyo) ; 70(3): 273-279, 2024.
Article in English | MEDLINE | ID: mdl-38945893

ABSTRACT

The purpose of this study was to examine whether 4 wk of daily ingestion of milk fat globule membrane (MFGM) combined with exercise training improves physical performance-muscle strength, agility and muscle power-in healthy young adults. The study was designed as a randomized, double-blind, and placebo-controlled trial. Twenty healthy young adults received either an MFGM powder containing 1.6 g of fat and 160 mg of sphingomyelin or an isocaloric placebo powder daily throughout 4 wk of power or agility training. Physical performance tests and body composition measurements were conducted before and after the 4-wk intervention. Ingestion of MFGM did not affect isometric or isokinetic muscle strength, but it was associated with a greater increase in vertical jump peak power compared with placebo. There were no significant changes in body weight or lean body mass during the intervention period in either group, and no significant differences between groups. We conclude that daily MFGM supplementation combined with exercise training has the potential to improve physical performance in young adults; however, further studies with larger sample sizes should be conducted to obtain more evidence supporting achievement of improved physical performance through MFGM supplementation.


Subject(s)
Body Composition , Dietary Supplements , Exercise , Glycolipids , Glycoproteins , Lipid Droplets , Muscle Strength , Humans , Double-Blind Method , Glycolipids/administration & dosage , Glycolipids/pharmacology , Glycoproteins/administration & dosage , Male , Young Adult , Female , Muscle Strength/drug effects , Exercise/physiology , Pilot Projects , Adult , Physical Functional Performance , Body Weight , Sphingomyelins/administration & dosage , Muscle, Skeletal/physiology , Muscle, Skeletal/drug effects
6.
Drug Deliv Transl Res ; 14(8): 2079-2084, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38388815

ABSTRACT

Achieving a controlled release of several active pharmaceutical ingredients (APIs) remains a challenge for improving their therapeutic effects and reduced their side effects. In the current work, stimulable Drug Delivery Systems (DDS) based on supramolecular hydrogels were designed by combining two APIs featuring anticancer activities, namely the doxorubicin and phenazine 14. In vitro studies revealed promising physicochemical properties for all the investigated API loaded gels. Fluorinated GlycoNucleoLipid (GNF) based supramolecular gels remain stable in the presence of either doxorubicin (Doxo) or phenazine 14 (Phe) as anticancer drugs. Noteworthy, the stiffness of the GNF-based supramolecular gels was enhanced in the presence of both APIs while maintaining their thixotropic properties. We demonstrated that the storage modulus (G') of the GNF gels was increased from 1.3 kPa to 9.3 kPa upon loading of both APIs within the same gels. With a low mechanical stimulation (within the LVR), a passive diffusion out of gels was observed for Dox whereas Phe remained trapped in the GNF gels over several hours. Also, in this work we showed that mechanical stress triggered the release of both Phe and Doxo at different rates.


Subject(s)
Doxorubicin , Drug Liberation , Glycolipids , Hydrogels , Hydrogels/chemistry , Hydrogels/administration & dosage , Doxorubicin/chemistry , Doxorubicin/administration & dosage , Glycolipids/chemistry , Glycolipids/administration & dosage , Phenazines/chemistry , Halogenation , Drug Delivery Systems , Antineoplastic Agents/chemistry , Antineoplastic Agents/administration & dosage , Delayed-Action Preparations/chemistry
7.
Mol Nutr Food Res ; 66(22): e2200177, 2022 11.
Article in English | MEDLINE | ID: mdl-36068654

ABSTRACT

SCOPE: Milk fat globule membrane (MFGM) is an essential component of milk. Bovine MFGM (bMFGM) has been shown to support cognitive development and increase relative concentrations of serum phospholipids. This study investigates bioavailability of bMFGM components after oral administration in two preclinical models to explore whether dietary bMFGM induces parallel changes to plasma and brain lipidomes. METHODS AND RESULTS: Transgenic APOE*3.Leiden mice (n = 18 per group) and Sprague-Dawley rats (n = 12 per group) are fed bMFGM-enriched (MFGM+) or Control diet, followed by phospholipid profile-determination in plasma, hippocampus, and prefrontal cortex tissue by targeted mass spectrometry. Multivariate analysis of lipidomic profiles demonstrates a separation between MFGM+ and Control plasma across rodents. In plasma, sphingomyelins contributed the most to the separation of lipid patterns among both models, where three sphingomyelins (d18:1/14:0, d18:1/23:0, d18:1/23:1[9Z]) are consistently higher in the circulation of MFGM+ groups. A similar trend is observed in rat prefrontal cortex, although no significant separation of the brain lipidome is demonstrated. CONCLUSION: bMFGM-enriched diet alters plasma phospholipid composition in rodents, predominantly increasing sphingomyelin levels in the systemic circulation with similar, but non-significant, trends in central brain regions. These changes may contribute to the beneficial effects of bMFGM on neurodevelopment during early life.


Subject(s)
Dietary Supplements , Glycolipids , Glycoproteins , Lipid Droplets , Lipidomics , Animals , Mice , Rats , Brain , Lipid Droplets/chemistry , Phospholipids/pharmacology , Rats, Sprague-Dawley , Sphingomyelins/pharmacology , Glycoproteins/administration & dosage , Glycolipids/administration & dosage
8.
J Sci Food Agric ; 102(3): 908-919, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34235749

ABSTRACT

BACKGROUND: Rhamnolipids (RLS), well known as glycolipid biosurfactants, display low toxicity, high biodegradability, and strong antibacterial properties. This study was carried out to evaluate the use of RLS supplementation as a substitute for antibiotics, and particularly to evaluate its effects on growth performance, immunity, intestinal barrier function, and metabolome composition in broilers. RESULTS: The RLS treatment improved the growth performance, immunity, and intestinal barrier function in broilers. The 16S rRNA sequencing revealed that the genus Alistipes was the dominant genus in broilers treated by RLS. An ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS)-based metabolomic analysis indicated that the sphingolipid metabolism, glycine, serine, and threonine metabolism, the gycerophospholipid metabolism, and the tryptophan metabolism were changed in broilers that were treated with RLS. CONCLUSION: l-Tryptophan may be the medium for RLS to regulate the growth and physiological metabolism. Rhamnolipids can be used as a potential alternative to antibiotics, with similar functions to antibiotics in the diet of broilers. The optimal level of supplemented RLS in the diet was 1000 mg kg-1 . © 2021 Society of Chemical Industry.


Subject(s)
Chickens/growth & development , Chickens/immunology , Glycolipids/administration & dosage , Intestines/immunology , Metabolome/drug effects , Animal Feed/analysis , Animals , Bacteria/classification , Bacteria/drug effects , Bacteria/genetics , Bacteria/isolation & purification , Chickens/metabolism , Chickens/microbiology , Dietary Supplements/analysis , Gastrointestinal Microbiome/drug effects , Intestines/metabolism , Intestines/microbiology , Metabolomics
9.
Blood ; 139(8): 1135-1146, 2022 02 24.
Article in English | MEDLINE | ID: mdl-34543383

ABSTRACT

Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A phase 1/2 study evaluated the safety, tolerability, and antileukemic activity of uproleselan (5-20 mg/kg) with MEC (mitoxantrone, etoposide, and cytarabine) among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Among the first 19 patients, no dose-limiting toxicities were observed. The recommended phase 2 dose (RP2D) was 10 mg/kg twice daily. An additional 47 patients with R/R AML were treated with uproleselan at the RP2D plus MEC. At the RP2D, the remission rate (complete response [CR]/CR with incomplete count recovery [CRi]) was 41% (CR, 35%), and the median overall survival (OS) was 8.8 months. In a separate cohort, 25 newly diagnosed patients age ≥60 years received uproleselan at the RP2D plus cytarabine and idarubicin (7 + 3). In these frontline patients, the CR/CRi rate was 72% (CR, 52%), and the median OS was 12.6 months. The addition of uproleselan was associated with low rates of oral mucositis. E-selectin ligand expression on leukemic blasts was higher in patients with relapsed vs primary refractory AML and in newly diagnosed older patients with high-risk cytogenetics and secondary AML. In the R/R cohort, E-selectin expression >10% was associated with a higher response rate and improved survival. The addition of uproleselan to chemotherapy was well tolerated, with high remission rates, low induction mortality, and low rates of mucositis, providing a strong rationale for phase 3 randomized confirmatory studies. This trial was registered at www.clinicaltrials.gov as #NCT02306291.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Glycolipids/administration & dosage , Leukemia, Myeloid, Acute , Adult , Age Factors , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cytarabine/administration & dosage , Cytarabine/adverse effects , Disease-Free Survival , Etoposide/administration & dosage , Etoposide/adverse effects , Female , Glycolipids/adverse effects , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Mitoxantrone/administration & dosage , Mitoxantrone/adverse effects , Survival Rate
10.
Nutrients ; 13(12)2021 Dec 18.
Article in English | MEDLINE | ID: mdl-34960093

ABSTRACT

Inclusion of bovine-derived milk fat globule membrane (bMFGM) or bMFGM components in infant formulas (IFs) may support healthy brain development. This double-blind, prospective trial evaluated growth, tolerance, and iron status in infants receiving added bMFGM and modified protein, iron, and arachidonic acid (ARA) concentrations in IF. Healthy term infants were randomized to: control (marketed, routine cow's milk-based IF/100 kcal: 2.1 g protein, 1.8 mg iron, 34 mg ARA) or INV-MFGM (investigational cow's milk-based IF/100 kcal: 1.9 g protein, 1.2 mg iron, 25 mg ARA and whey protein-lipid concentrate, 5 g/L (source of bMFGM)). Anthropometrics, stool characteristics, fussiness, and gassiness through day 365 and blood markers of iron status at day 365 were evaluated. The primary outcome was rate of weight gain from 14-120 days of age. Of 373 infants enrolled (control: 191, INV-MFGM: 182), 275 completed the study (control: 141; INV-MFGM: 134). No group differences in growth rate (g/day) from day 14-120 or study discontinuation were detected. Few group differences in growth or parent-reported fussiness, gassiness, or stool characteristics were detected. No group differences were detected in hemoglobin, hematocrit, or incidence of anemia. In healthy term infants, bMFGM and modified protein, iron, and ARA concentrations in a cow's milk-based IF were well-tolerated, associated with adequate growth throughout the first year of life, and supported normal iron status at one year of age.


Subject(s)
Child Development/physiology , Food, Fortified , Glycolipids/administration & dosage , Glycoproteins/administration & dosage , Infant Formula , Infant Nutritional Physiological Phenomena , Iron, Dietary/administration & dosage , Iron/metabolism , Age Factors , Female , Humans , Infant , Infant, Newborn , Lipid Droplets , Male
11.
Front Immunol ; 12: 727300, 2021.
Article in English | MEDLINE | ID: mdl-34887849

ABSTRACT

Upon infection with Mycobacterium tuberculosis (Mtb) the host immune response might clear the bacteria, control its growth leading to latent tuberculosis (LTB), or fail to control its growth resulting in active TB (ATB). There is however no clear understanding of the features underlying a more or less effective response. Mtb glycolipids are abundant in the bacterial cell envelope and modulate the immune response to Mtb, but the patterns of response to glycolipids are still underexplored. To identify the CD45+ leukocyte activation landscape induced by Mtb glycolipids in peripheral blood of ATB and LTB, we performed a detailed assessment of the immune response of PBMCs to the Mtb glycolipids lipoarabinomannan (LAM) and its biosynthetic precursor phosphatidyl-inositol mannoside (PIM), and purified-protein derivate (PPD). At 24 h of stimulation, cell profiling and secretome analysis was done using mass cytometry and high-multiplex immunoassay. PIM induced a diverse cytokine response, mainly affecting antigen-presenting cells to produce both pro-inflammatory and anti-inflammatory cytokines, but not IFN-γ, contrasting with PPD that was a strong inducer of IFN-γ. The effect of PIM on the antigen-presenting cells was partly TLR2-dependent. Expansion of monocyte subsets in response to PIM or LAM was reduced primarily in LTB as compared to healthy controls, suggesting a hyporesponsive/tolerance pattern derived from Mtb infection.


Subject(s)
Latent Tuberculosis/immunology , Tuberculosis/immunology , Adult , Aged , Aged, 80 and over , Antigens, Bacterial/administration & dosage , Antigens, Bacterial/immunology , B-Lymphocytes/classification , B-Lymphocytes/immunology , Case-Control Studies , Cohort Studies , Cytokines/biosynthesis , Female , Glycolipids/administration & dosage , Glycolipids/immunology , Humans , In Vitro Techniques , Killer Cells, Natural/immunology , Male , Middle Aged , Mycobacterium tuberculosis/immunology , Myeloid Cells/immunology , Phosphatidylinositols/administration & dosage , Phosphatidylinositols/immunology , Prospective Studies , T-Lymphocytes/classification , T-Lymphocytes/immunology , Toll-Like Receptor 2/immunology , Tuberculin/administration & dosage , Tuberculin/immunology , Young Adult
12.
Nutrients ; 13(12)2021 Nov 26.
Article in English | MEDLINE | ID: mdl-34959820

ABSTRACT

Brown adipose tissue (BAT) activation is associated with increased energy expenditure by inducing non-shivering thermogenesis. The ingestion of a milk fat globule membrane (MFGM) supplement and a high calorie diet are reported gateways into BAT activation. However, little is known about the effect of the MFGM and high calorie diets on BAT volume. To gain insight into this, mice were maintained on a high-fat (HF) or low-fat (LF) diet in conjunction with either full-cream (FC) or skim bovine dairy milk (BDM). After being maintained on their respective diets for 13 weeks, their body composition, including BAT volume, was measured using X-ray microtomography. A high calorie diet resulted in an increase in the BAT volume and mice consuming an HF diet in conjunction with FC BDM had a significantly greater BAT volume than all the other groups. Conversely, mice consuming an HF diet in addition to skim milk had a lower BAT volume compared to the HF control. The data presented suggest that the consumption of a high calorie diet in conjunction with FC BDM increases the BAT volume in wild-type mice. This study may provide valuable insight into future studies investigating BAT volume and BAT activity in relation to environmental factors, including diet.


Subject(s)
Adipose Tissue, Brown/drug effects , Body Composition/drug effects , Eating/drug effects , Glycolipids/administration & dosage , Glycoproteins/administration & dosage , Milk/chemistry , Animals , Cattle , Diet, Fat-Restricted/methods , Diet, High-Fat/methods , Lipid Droplets , Lipids/administration & dosage , Mice , Thermogenesis/drug effects
13.
Nat Commun ; 12(1): 7264, 2021 12 14.
Article in English | MEDLINE | ID: mdl-34907171

ABSTRACT

Antibodies targeting costimulatory receptors of T cells have been developed for the activation of T cell immunity in cancer immunotherapy. However, costimulatory molecule expression is often lacking in tumor-infiltrating immune cells, which can impede antibody-mediated immunotherapy. Here, we hypothesize that delivery of costimulatory receptor mRNA to tumor-infiltrating T cells will enhance the antitumor effects of antibodies. We first design a library of biomimetic nanoparticles and find that phospholipid nanoparticles (PL1) effectively deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Then, we demonstrate that the combination of PL1-OX40 mRNA and anti-OX40 antibody exhibits significantly improved antitumor activity compared to anti-OX40 antibody alone in multiple tumor models. This treatment regimen results in a 60% complete response rate in the A20 tumor model, with these mice being resistant to rechallenge by A20 tumor cells. Additionally, the combination of PL1-OX40 mRNA and anti-OX40 antibody significantly boosts the antitumor immune response to anti-PD-1 + anti-CTLA-4 antibodies in the B16F10 tumor model. This study supports the concept of delivering mRNA encoding costimulatory receptors in combination with the corresponding agonistic antibody as a strategy to enhance cancer immunotherapy.


Subject(s)
Biomimetic Materials/administration & dosage , Immunotherapy/methods , Lymphocytes, Tumor-Infiltrating/immunology , Nanoparticles/administration & dosage , RNA, Messenger/administration & dosage , T-Lymphocytes/immunology , Animals , Biomimetic Materials/chemistry , Drug Delivery Systems , Glycolipids/administration & dosage , Glycolipids/chemistry , Lymphocytes, Tumor-Infiltrating/metabolism , Mice , Nanoparticles/chemistry , Neoplasms, Experimental/immunology , Neoplasms, Experimental/therapy , Phospholipids/administration & dosage , Phospholipids/chemistry , RNA, Messenger/chemistry , Receptors, OX40/antagonists & inhibitors , Receptors, OX40/genetics , Receptors, OX40/immunology , Receptors, OX40/metabolism , T-Lymphocytes/metabolism , Tumor Necrosis Factor Receptor Superfamily, Member 9/antagonists & inhibitors , Tumor Necrosis Factor Receptor Superfamily, Member 9/genetics , Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology , Tumor Necrosis Factor Receptor Superfamily, Member 9/metabolism
14.
Nutrients ; 13(9)2021 Aug 25.
Article in English | MEDLINE | ID: mdl-34578827

ABSTRACT

The human milk fat globule membrane (MFGM) contains important lipids for growing infants. Anthropometric measurements, milk samples, and infant milk intake were collected in a cohort of eleven healthy mother-infant dyads during exclusive breastfeeding from birth to six months. One hundred and sixty-six MFGM lipids were analysed using liquid chromatography-mass spectrometry, and the infant intake was calculated. The concentrations and intake were compared and associations between infant intake and growth characteristics explored. The lipid concentrations and infant intake varied widely between mother-infant dyads and between months one and three. The infant intake for many species displayed positive correlations with infant growth, particularly phospholipid species. The high variation in lipid intake is likely an important factor in infant growth, with strong correlations identified between the intake of many MFGM lipids and infant head circumference and weight. This study highlights the need for intake measurements and inclusion in cohort studies to elucidate the role of the human milk lipidome in infant growth and development.


Subject(s)
Breast Feeding/statistics & numerical data , Glycolipids/administration & dosage , Glycolipids/analysis , Glycoproteins/administration & dosage , Glycoproteins/analysis , Milk, Human/chemistry , Adult , Chromatography, Liquid , Female , Humans , Infant , Lipid Droplets , Longitudinal Studies , Male , Mass Spectrometry , Reference Values , Western Australia
15.
Nutrients ; 13(7)2021 Jul 05.
Article in English | MEDLINE | ID: mdl-34371820

ABSTRACT

Morphological changes in neuromuscular junctions (NMJs), which are synapses formed between α-motor neurons and skeletal muscle fibers, are considered to be important in age-related motor dysfunction. We have previously shown that the intake of dietary milk fat globule membrane (MFGM) combined with exercise attenuates age-related NMJ alterations in the early phase of aging. However, it is unclear whether the effect of MFGM with exercise on age-related NMJ alterations persists into old age, and whether intervention from old age is still effective when age-related changes in NMJs have already occurred. In this study, 6- or 18-month-old mice were treated with a 1% MFGM diet and daily running wheel exercise until 23 or 24 months of age, respectively. MFGM treatment with exercise was effective in suppressing the progression of age-related NMJ alterations in old age, and even after age-related changes in NMJs had already occurred. Moreover, the effect of MFGM intake with exercise was not restricted to NMJs but extended to the structure and function of peripheral nerves. This study demonstrates that MFGM intake with exercise may be a novel approach for improving motor function in the elderly by suppressing age-related NMJ alterations.


Subject(s)
Aging/physiology , Animal Nutritional Physiological Phenomena/drug effects , Glycolipids/administration & dosage , Glycoproteins/administration & dosage , Neuromuscular Junction/drug effects , Physical Conditioning, Animal/physiology , Animals , Dietary Supplements , Lipid Droplets , Mice , Motor Neurons/drug effects , Muscle Fibers, Skeletal/drug effects , Synapses/drug effects
16.
Eur J Pharm Biopharm ; 165: 293-305, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34044110

ABSTRACT

The degree of antigen adsorption to adjuvants in subunit vaccines may significantly influence the immune responses they induce upon vaccination. Commonly used approaches for studying how the level of adsorption affects the induction of antigen-specific immune responses include (i) using adjuvants with different abilities to adsorb antigens, and (ii) comparing different antigens selected based on their ability to adsorb to the adjuvant. A weakness of these approaches is that not only the antigen adsorption level is varied, but also other important functional factors such as adjuvant composition and/or the B/T cell epitopes, which may affect immunogenicity. Hence, we investigated how changing the adsorption capabilities of a single antigen to an adjuvant influenced the vaccine-induced immune responses. The model antigen lysozyme, which displays a positive net charge at physiological pH due to an isoelectric point (pI) of 11, was succinylated to different extents, resulting in a reduction of the pI value to 4.4-5.9, depending on the degree of succinylation. A pronounced inverse correlation was found between the pI value of the succinylated lysozyme analogues and the degree of adsorption to a cationic liposomal adjuvant consisting of dimethyldioctadecylammonium bromide (DDA) and trehalose dibehenate (TDB) (CAF®01). Furthermore, increased adsorption to this adjuvant correlated directly with the magnitude of lysozyme-specific Th1/Th17 immune responses induced by the vaccine in mice, while there was an inverse correlation with antibody induction. However, high lysozyme-specific antibody titers were induced with an increased antigen dose, even upon vaccination with a strongly adsorbed succinylated lysozyme analogue. Hence, these data illustrate that the degree of lysozyme adsorption to CAF®01 strongly affects the quality of the resulting immune responses.


Subject(s)
Adjuvants, Immunologic/chemistry , Antigens/immunology , Vaccines, Subunit/immunology , Adjuvants, Immunologic/administration & dosage , Adsorption , Animals , Antigens/administration & dosage , Antigens/chemistry , Cations/administration & dosage , Cations/chemistry , Female , Glycolipids/administration & dosage , Glycolipids/chemistry , Immunogenicity, Vaccine , Liposomes , Mice , Models, Animal , Muramidase/administration & dosage , Muramidase/chemistry , Muramidase/immunology , Quaternary Ammonium Compounds/administration & dosage , Quaternary Ammonium Compounds/chemistry , Th1 Cells , Th17 Cells , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/chemistry
17.
Nutrients ; 13(4)2021 Apr 10.
Article in English | MEDLINE | ID: mdl-33920187

ABSTRACT

Various proteins or protein fractions reportedly positively affect gastrointestinal integrity and inflammation in diets providing >45% energy as fat. This study tested whether benefits were seen in diets providing 30% of energy as fat. Purified diets (PD) with isolated soy protein (ISP), dried whole milk powder (DWMP), milk fat globule membrane (MFGM), or milk protein concentrate (MPC) as protein sources were fed to C57BL/6J mice (n = 15/diet group) for 13 weeks. MFGM-fed mice were heaviest (p < 0.005) but remained within breeder norms. Growth rates and gut motility were similar for all PD-fed mice. FITC-dextran assessed gut permeability was lowest in DWMP and MFGM (p = 0.054); overall, plasma endotoxin and unprovoked circulating cytokines indicated a non-inflammatory state for all PD-fed mice. Despite differences in cecal butyrate and intestinal gene expression, all PDs supported gastrointestinal health. Whole milk provided more positive effects compared to its fractions. However, ISP-fed mice showed a >370%, (p < 0.006) increase in colonic myeloperoxidase activity indicative of tissue neutrophil infiltration. Surprisingly, FITC-dextran and endotoxin outcomes were many folds better in PD-fed mice than mice (strain, vendor, age and sex matched) fed a "chow-type" nutritionally adequate non-PD. Additional variables within a diet's matrix appear to affect routine indicators or gastrointestinal health.


Subject(s)
Feeding Behavior/physiology , Gastrointestinal Tract/physiology , Glycolipids/administration & dosage , Glycoproteins/administration & dosage , Milk Proteins/administration & dosage , Soybean Proteins/administration & dosage , Animal Feed , Animals , Biomarkers , Gastrointestinal Motility , Lipid Droplets , Male , Mice , Mice, Inbred C57BL , Models, Animal
18.
J Nutr ; 151(6): 1487-1496, 2021 06 01.
Article in English | MEDLINE | ID: mdl-33693864

ABSTRACT

BACKGROUND: Exposure to a maternal high-fat diet (HFD) predisposes offspring to nonalcoholic fatty liver disease. OBJECTIVES: The aim of this study was to explore whether milk fat globule membrane (MFGM) supplementation during suckling exerts a long-term protective effect on hepatic lipid metabolism in adult offspring exposed to maternal HFD. METHODS: We fed 5-week-old female C57BL/6J mice either a HFD (60% kcal fat) or control diet (CD; 16.7% kcal fat) for 3 weeks before mating, as well as throughout gestation and lactation. After delivery, male offspring from HFD dams were supplemented with 1 g/(kg body weight·day) MFGM (HFD + MFGM group) or the same volume of vehicle (HFD group) during suckling. Male offspring from CD dams were also supplemented with vehicle during suckling (CD group). All offspring were weaned onto CD for 8 weeks. Histopathology, metabolic parameters, lipogenic level, oxidative stress, and mitochondria function in the liver were analyzed. A 1-way ANOVA and a Kruskal-Wallis test were used for multi-group comparisons. RESULTS: As compared to the CD group, the HFD group had more lipid droplets in livers, and exhibited ∼100% higher serum triglycerides, ∼38% higher hepatic triglycerides, ∼75% higher serum aspartate aminotransferase, and ∼130% higher fasting blood glucose (P < 0.05). The changes of these metabolic parameters were normalized in the HFD + MFGM group. Phosphorylated mammalian targets of rapamycin and AKT were downregulated, but phosphorylated adenosine monophosphate-activated protein kinase was upregulated in the HFD + MFGM group as compared to the HFD group (P < 0.05). As compared to the CD group, the HFD group showed an ∼80% higher malondialdehyde level, and ∼20% lower superoxide dismutase activity (P < 0.05), which were normalized in the HFD + MFGM group. Additionally, mitochondria function was also impaired in the HFD group and normalized in the HFD + MFGM group. CONCLUSIONS: MFGM supplementation during suckling ameliorates maternal HFD-induced hepatic steatosis in mice via suppressing de novo lipogenesis, reinforcing antioxidant defenses and improving mitochondrial function.


Subject(s)
Diet, High-Fat , Fatty Liver/prevention & control , Glycolipids/administration & dosage , Glycoproteins/administration & dosage , Maternal Nutritional Physiological Phenomena , Animals , Aspartate Aminotransferases/blood , Blood Glucose , Diet, High-Fat/adverse effects , Dietary Supplements , Female , Lipid Droplets , Liver , Male , Mice , Mice, Inbred C57BL , Triglycerides/analysis
19.
Nutrients ; 13(3)2021 Feb 24.
Article in English | MEDLINE | ID: mdl-33668227

ABSTRACT

(1) Background: Milk fat globule membrane (MFGM), composing fat droplets responsible for lipid transport in breast milk, has been shown to possess immunological and antimicrobial effects. Standard formulas (SF) are devoid of MFGMs during the production process. The study's aim was to evaluate the safety and benefits of MFGMs supplementation in children. (2) Methods: We searched four databases for randomized controlled trials evaluating the supplementation of MFGMs in children. Growth parameters were chosen as the primary outcome. (3) Results: Twenty-four publications of seventeen studies were included. Meta-analyses assessing the primary outcomes at the age of 4 months included four studies (814 children) comparing the MFGM-supplemented formulas and SF, and two trials (549 children) comparing the MFGM-supplemented formulas and breastfeeding. The primary outcomes were non-inferior in all the experimental MFGM formulas compared to SF, or even represented more similar results to breastfed infants. The promising effects, including a lower incidence of acute otitis media and improved cognitive development, cannot be firmly confirmed due to the small amount of existing evidence. No significant adverse effects were reported in any of the assessed products. (4) Conclusions: The available data signaled beneficial effects and a good safety profile, requiring future research with well-designed trials.


Subject(s)
Child Development/drug effects , Cognition/drug effects , Dietary Supplements , Glycolipids/administration & dosage , Glycoproteins/administration & dosage , Infant Formula/chemistry , Breast Feeding , Female , Humans , Infant , Lipid Droplets , Male , Milk, Human/chemistry , Randomized Controlled Trials as Topic
20.
Poult Sci ; 100(2): 810-819, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33518135

ABSTRACT

This study determined the effects of dietary supplementation of rhamnolipids (RLS) on the growth performance, gut morphology, immune function, intestinal volatile fatty acid, and microflora community in Linnan yellow broilers. A total of 480 1-day-old broiler chicks were randomly assigned to groups for supplementation with one of the following for 56 d: no supplement (control), 30 mg/kg bacitracin (ANT), 500 mg/kg RLS, or 1,000 mg/kg RLS (RLS2). The RLS2 diet was found to improve the final BW and ADG on day 56. The RLS diet reduced jejunal crypt depth, increased jejunal villus length, and increased serum IgA, IgM, IgY, IL-1ß, IL-6, and tumor necrosis factor-alpha (TNF-α) levels. The RLS broilers had higher cecum concentrations of acetic acid, propionic acid, butyrate, isobutyric acid, valerate, and isovalerate. High-throughput sequencing indicated that RLS affected microbial quantity and diversity in the cecum. Bacterial richness was higher in the RLS broilers than the ANT broilers. The RLS broilers had higher relative abundances of Megasphaera hypermegale and Lachnospiraceae bacterium 19gly4 on day 28 and Clostridium spiroforme and Alistipes obesi on day 56. These results suggest that RLS supplementation improves growth performance, benefits the intestinal villus morphology, regulates host immune function, and raises intestinal volatile fatty acid content and the relative abundance of the gut microbiota in broiler chickens.


Subject(s)
Animal Feed , Chickens , Glycolipids/administration & dosage , Intestines/physiology , Animal Feed/analysis , Animals , Bacteroidetes/growth & development , Chickens/classification , Chickens/growth & development , Chickens/physiology , Diet/veterinary , Dietary Supplements , Firmicutes/growth & development , Intestines/growth & development , Intestines/microbiology , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL